注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Arvinas Inc是一家處於臨床階段的生物技術公司。該公司從事降解致病蛋白質的療法的發現、開發和商業化。該公司利用其蛋白分解靶向嵌合體(PROTAC)發現引擎這一技術平臺來設計PROTAC靶向蛋白降解劑,旨在利用人體自身的天然蛋白處理系統來選擇性地清除致病蛋白。其三個候選產品包括ARV-110、ARV-471和ARV-766。該公司開發的ARV-110是一種針對雄性激素受體蛋白(AR)的PROTAC蛋白降解劑,用於治療男性轉移性耐閹割前列腺癌(mCRPC)。該公司開發了ARV-471,一種針對雌激素受體蛋白(ER)的PROTAC蛋白降解劑,用於治療局部晚期或轉移性ER陽性、HER2陰性乳腺癌患者。該公司開發了ARV-766,一種PROTAC蛋白降解劑,用於治療男性mCRPC患者。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Linda Cathavina Bain | 53 | 2020 | Independent Director |
Sunil Agarwal | 53 | 2023 | Independent Director |
Bradley T. Hyman | - | 2022 | Member of Scientific Advisory Board |
John G. Houston | 63 | 2017 | Chairperson, CEO & President |
John D. Young | 58 | 2022 | Independent Director |
Everett V. Cunningham | 57 | 2022 | Independent Director |
Michelle Arkin | - | 2023 | Member of Scientific Advisory Board |
Susan Kaech | - | 2022 | Member of Scientific Advisory Board |
Edward Moore Kennedy | 62 | 2018 | Independent Director |
Benjamin G. Neel | - | 2019 | Member of Scientific Advisory Board |
Laurie Smaldone Alsup | 69 | 2019 | Independent Director |
Leslie V. Norwalk | 58 | 2019 | Independent Director |
Adam L. Boxer | - | 2019 | Member of Scientific Advisory Board |
Briggs W. Morrison | 63 | 2018 | Lead Independent Director |
Wendy L. Dixon | 68 | 2020 | Independent Director |
Lillian L. Siu | - | 2019 | Member of Scientific Advisory Board |
Lennart Mucke | - | 2019 | Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核